Navigation Links
Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting

Data From the Companies' Novel Heat Shock Protein 90 Inhibitor Reveal Further Evidence of Safety, Tolerability, and Biological Activity

CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced updated interim results from a Phase I clinical trial of the companies' heat shock protein 90 (Hsp90) inhibitor, IPI-504, in patients with relapsed, refractory gastrointestinal stromal tumors (GIST) and other advanced soft tissue sarcomas. The data, presented at the 2007 Annual Meeting of the American Society for Clinical Oncology (ASCO), indicate that IPI-504 continues to be well tolerated and to show evidence of biological activity.

To date, 28 patients have received IPI-504 on two schedules of administration at dose levels ranging from 90 to 400 mg/m2. Assessment of biological activity in response to IPI-504 administration utilized positron emission tomography (PET) imaging to measure the decrease in tumor uptake of 18-fluorodeoxyglucose, an imaging agent used to measure metabolic activity. Scans were taken at baseline and during the first cycle of treatment after at least two doses. PET results for "Schedule A" (21-day cycle with patients treated on days 1, 4, 8, and 11, followed by 10 days off treatment) were assessed using the European Organization for Research and Treatment of Cancer's (EORTC) PET response criteria which entails a quantitative measurement using SUVmax (maximum standardized uptake value). PET results for "Schedule B" (uninterrupted twice-weekly dosing without a drug holiday) were assessed qualitatively. (See below for additional information about PET imaging and SUVmax.)

EORTC criteria for PET responses define Stable Disease as a change in SUVmax between 25 percent above and 25 percent below baseline, and a Partial Response as a decrease in SUVmax of 25 percent or more
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
2. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. The Past, Present and Future of HLA Typing
11. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
(Date:1/14/2014)... 2014   NuAire , a manufacturer of ergonomically designed laboratory ... Koki of Japan to sell and ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
(Date:4/18/2014)... news release is available in French . ... could revolutionize surgical practice and regenerative medicine. A team ... et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from ... Paris 13), has just demonstrated that the principle of ... in vivo to repair soft-tissue organs and tissues. This ...
(Date:4/17/2014)... Men who show signs of chronic inflammation in non-cancerous ... actually having prostate cancer than those with no inflammation, ... researchers from the Johns Hopkins Kimmel Cancer Center. , ... stronger for men with so-called high-grade prostate cancer ... indicating the presence of the most aggressive and ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... In a study that could point to novel therapies to ... California, San Diego (UCSD) School of Medicine have targeted ... ,Lung cancer is the most common cause of ... metastasis are desperately needed, according to first author Mark M. ...
... from the SCIAMACHY instrument aboard ESAs environmental satellite ... hovering over Australia during the wildfire season ... 000 kilometres away. , ,Using SCIAMACHY, ... Research and her colleagues at Utrecht University, the ...
... and Drug Administration, the Purdue pharma of the US ... their popular painkiller Oxycontin. ,They have agreed to ... drug to boost sales and also pleaded guilty to charges ... ,Purdue pleaded guilty to a felony count of misbranding a ...
... ducks from Matigara, Darjeeling District in West Bengal & Kuttanad ... & H7) as per report received from High Animal Security ... been reported from these two places. ,In ... in death of 2500 birds on 5-6th May, 2007. A ...
... foods such as peanuts, tree nuts, milk and more ... to open a new clinic that will include a focus ... Dominos Farms in north Ann Arbor offers an expansion of ... Specialty Clinic and Food Allergy Clinic will be a regional ...
... Mental Health of the National Institutes of Health has ... research grant to test schizophrenic patients for a ... is led by Stephen T. Warren, PhD, Timmie Professor ... ,Schizophrenia is a severe and common psychiatric disorder ...
Cached Medicine News:Health News:Targeting Sugar on Blood Vessels may Inhibit Cancer Growth 2Health News:Transcontinental Wildfire Emissions Monitored from Space 2Health News:US Drugmaker Slapped Huge Fine for Misleading Doctors Over Addictive Painkiller 2Health News:NIH Awards Emory $3.6 Million for Schizophrenia Gene Research 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: